Hepatitis Group, ICMR-National Institute of Virology, Pune, 130/1, Sus Road, Pashan, Pune, Maharashtra, 411021, India.
Med Microbiol Immunol. 2020 Apr;209(2):109-124. doi: 10.1007/s00430-019-00648-z. Epub 2019 Nov 28.
The complement system is a critical component of both innate and adaptive immune responses. It has both protective and pathogenic roles in viral infections. There are no studies regarding the role of complement system in Chandipura virus (CHPV) infection. The current study has investigated the role of complement pathways in the in vitro neutralization of CHPV in Vero E6 cells. Using normal human serum (NHS), heat-inactivated serum (HIS), human serum deficient of complement factor, respective reconstituted serum, assays like in vitro neutralization, real-time PCR, and flow cytometry-based tissue culture-based limited dose assay (TC-LDA) were carried out for assessing the activation of different complement pathways. NHS from 9/10 donors showed complement dependent neutralization, reduction in viral load and decrease in percentage of CHPV-positive cells compared to their HIS counterparts. EGTA or EDTA pretreatment experiments indicated that CHPV neutralization proceeds through the alternative pathway of the complement activation. Our data showed a strong dependence on C3 for the in vitro neutralization of CHPV. Disparity in CHPV neutralization levels between factor B-deficient and reconstituted sera could be attributed to amplification loop/"tick-over" mechanism. Assays using C3, C5, and C8 deficient sera indicated that complement-mediated CHPV neutralization and suppression of CHPV infectivity are primarily through C3 and C5, and not dependent on downstream complement factor C8. With no specific anti-viral treatment/vaccine against Chandipura, the current data, elucidating role of human complement system in the neutralization of CHPV, may help in designing effective therapeutics.
补体系统是先天和适应性免疫反应的关键组成部分。它在病毒感染中具有保护和致病作用。目前还没有关于补体系统在 Chandipura 病毒(CHPV)感染中的作用的研究。本研究探讨了补体途径在 Vero E6 细胞中体外中和 CHPV 的作用。使用正常人血清(NHS)、热失活血清(HIS)、缺乏补体因子的人血清、各自的重组血清,进行体外中和、实时 PCR 和基于组织培养的有限剂量测定(TC-LDA)的流式细胞术等测定,以评估不同补体途径的激活。来自 9/10 名供体的 NHS 显示补体依赖性中和,与 HIS 相比,病毒载量减少,CHPV 阳性细胞的百分比降低。EGTA 或 EDTA 预处理实验表明,CHPV 中和通过补体激活的替代途径进行。我们的数据表明,CHPV 的体外中和强烈依赖于 C3。因子 B 缺乏和重组血清之间 CHPV 中和水平的差异可能归因于扩增环/“滴答”机制。使用 C3、C5 和 C8 缺乏的血清进行的测定表明,补体介导的 CHPV 中和和抑制 CHPV 感染性主要通过 C3 和 C5,而不依赖于下游补体因子 C8。由于没有针对 Chandipura 的特定抗病毒治疗/疫苗,目前阐明人类补体系统在中和 CHPV 中的作用的数据可能有助于设计有效的治疗方法。